Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEVIATE-2: Epratuzumab in SLE
NCT00383214Phase 3Terminated
- Sponsor
- UCB
- Start
- May 2005
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of epratuzumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by UCB. Primary endpoint: Patient response variable (complete response, partial response, non-response) at 24 weeks. Started May 2005; status: terminated.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00383214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383214.